--- title: Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery nct_id: NCT02072486 overall_status: COMPLETED phase: NA sponsor: Roswell Park Cancer Institute study_type: INTERVENTIONAL primary_condition: Advanced Adult Hepatocellular Carcinoma countries: United States canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02072486.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02072486" ct_last_update_post_date: 2022-07-25 last_seen_at: "2026-05-12T06:18:33.585Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery **Official Title:** Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC **NCT ID:** [NCT02072486](https://clinicaltrials.gov/study/NCT02072486) ## Key Facts - **Status:** COMPLETED - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 30 - **Lead Sponsor:** Roswell Park Cancer Institute - **Collaborators:** National Comprehensive Cancer Network - **Conditions:** Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Hepatocellular Carcinoma, Stage III Childhood Hepatocellular Carcinoma, Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IV Childhood Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma, Stage IVB Hepatocellular Carcinoma - **Start Date:** 2013-11-18 - **Completion Date:** 2020-07-19 - **CT.gov Last Update:** 2022-07-25 ## Brief Summary This clinical trial studies sorafenib tosylate in treating patients with liver cancer that cannot be removed by surgery. Sorafenib tosylate may block some of the enzymes needed for tumor cell growth. Blocking these enzymes may also help the immune system work better. Granzyme B is a biomarker that can be used to measure how well the immune system is working. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. Studying granzyme B levels in patients receiving sorafenib tosylate may help doctors learn more about the effects of sorafenib tosylate on the immune system and may help to predict how well sorafenib tosylate will work in treating patients with liver cancer. ## Detailed Description PRIMARY OBJECTIVES: I. To determine whether the proportion of cytotoxic T lymphocytes that are producing granzyme B (denoted pGrzB) as measured \~28-35 days after initiation of sorafenib (sorafenib tosylate) therapy correlates with overall survival, defined as the number of months between the start of sorafenib treatment and death from any cause. SECONDARY OBJECTIVES: I. To determine whether higher pGrzB levels will correlate with better sorafenib tolerance, manifested by fewer dose reductions, dose interruptions and adverse events. II. To determine whether improved immune function may also result in greater recognition of hepatitis viral antigens. OUTLINE: Patients receive sorafenib tosylate orally (PO) twice daily (BID). Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study, patients are followed up for 30 days or after the 6 month time point if continuing sorafenib tosylate and then periodically thereafter. ## Eligibility - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * Subject or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure * Outpatients with histologically/cytologically documented or radiographically diagnosed unresectable hepatocellular carcinoma (HCC) who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made; radiographic diagnosis needs typical findings of HCC by a radiographic method, i.e. on multi-dimensional dynamic computed tomography (CT), CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or magnetic resonance imaging (MRI) * Patients must have a life expectancy of at least 8 weeks * Patients must not have any evidence of bleeding diathesis or active gastrointestinal bleeding Exclusion Criteria: * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant or nursing female subjects * Unwilling or unable to follow protocol requirements * Any condition which in the investigator's opinion deems the subject an unsuitable candidate to receive study drug * Patients who have had prior anti-angiogenic therapy, including but not limited to sorafenib, brivanib, bevacizumab, or sunitinib; prior treatment with liver directed, ablative or surgical therapies will be permitted as long as there is documented progression justifying the need for starting sorafenib therapy * No known contraindications to anti-angiogenics such as severe coronary artery disease, recent myocardial infarction or stroke within 6 months, bleeding peptic ulcer or varices within last 3 months, and any other major illness that may jeopardize study treatment or follow up ``` ## Arms - **Treatment (sorafenib tosylate)** (EXPERIMENTAL) — Patients receive sorafenib tosylate PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity. ## Interventions - **Laboratory Biomarker Analysis** (OTHER) — Correlative studies - **Sorafenib Tosylate** (DRUG) — Given PO ## Primary Outcomes - **Granzyme B levels** _(time frame: Up to 35 days)_ — The pGrzB hazard ratio (per 10 percentage point increase) and the associated 95% confidence interval will be estimated using a Cox PH model. Whether pGrzB measurements vary by presence of grade 3+ adverse events (AEs) will be assessed using permutation independent sample t-tests. Descriptive statistics include the pGrzB mean, standard deviations and ranges within AE or patient characteristics. - **Overall survival (OS)** _(time frame: Time between start of first treatment and death, assessed up to 6 months)_ — The hazard ratio and 95% confidence interval for the effect of day \~28-35 pGrzB (in 10 percentage point increments) on OS will be estimated using proportional hazards (PH) models. The pGrzB functional form will be assessed using generalized additive models. Possible confounding from sorafenib dose differences and baseline characteristics will be assessed by including other covariates (or perhaps frailty terms) in the model. ## Secondary Outcomes - **Granzyme B level variations by presence of grade 3 or higher AE, characterized using National Cancer Institute Common Terminology Criteria for Adverse Events severity grade** _(time frame: Up to 30 days)_ ## Locations (1) - Roswell Park Cancer Institute, Buffalo, New York, United States ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `sponsor.collaborators` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.roswell park cancer institute|buffalo|new york|united states` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT02072486.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT02072486* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*